Lisata Therapeutics, Inc.
LSTA
$5.03
-$0.01-0.20%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -83.00% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -83.00% | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -83.00% | -- | -- | -- | -- |
| SG&A Expenses | -13.62% | -5.82% | -1.30% | -5.60% | -6.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.49% | -9.95% | -8.47% | -11.03% | -8.94% |
| Operating Income | 18.75% | 14.51% | 12.91% | 14.96% | 12.83% |
| Income Before Tax | 15.57% | 10.84% | 9.07% | 12.56% | 10.30% |
| Income Tax Expenses | -20.55% | -20.55% | -20.55% | 69.25% | 65.75% |
| Earnings from Continuing Operations | 17.01% | 12.04% | 10.19% | 3.72% | 4.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.01% | 12.04% | 10.19% | 3.72% | 4.10% |
| EBIT | 18.75% | 14.51% | 12.91% | 14.96% | 12.83% |
| EBITDA | 18.77% | 14.58% | 12.95% | 15.01% | 12.87% |
| EPS Basic | 20.31% | 15.29% | 12.92% | 6.53% | 7.05% |
| Normalized Basic EPS | 18.55% | 13.77% | 11.51% | 14.97% | 13.47% |
| EPS Diluted | 20.31% | 15.29% | 12.92% | 6.53% | 7.05% |
| Normalized Diluted EPS | 18.55% | 13.77% | 11.51% | 14.97% | 13.47% |
| Average Basic Shares Outstanding | 4.29% | 3.86% | 3.16% | 3.15% | 3.18% |
| Average Diluted Shares Outstanding | 4.29% | 3.86% | 3.16% | 3.15% | 3.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |